Biogen Inc
BIIB
View Detailed Chart
146.570USD
-3.040-2.03%
Close 10/10, 16:00（ET）Quotes delayed by 15 min
21.49BMarket Cap
14.04P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-2.03%
5 Days
-5.59%
1 Month
+2.07%
6 Months
+21.64%
Year to Date
-4.15%
1 Year
-21.10%
View Detailed Chart
TradingKey Stock Score of Biogen Inc
Currency: USD Updated: 2025-10-09Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Biogen Inc's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
36
analysts
Buy
Current Rating
170.560
Target Price
+12.98%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Biogen Inc Highlights
StrengthsRisks
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
Fairly Valued
The company’s latest PE is 14.28, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 135.68M shares, decreasing 6.03% quarter-over-quarter.
Held by PRIMECAP Management
Star Investor PRIMECAP Management holds 15.80M shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Biogen Inc Info
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
Ticker SymbolBIIB
CompanyBiogen Inc
CEOMr. Christopher A. (Chris) Viehbacher
Websitehttps://www.biogen.com/
Related Instruments
-2.53%
-0.19%
-0.04%
-0.60%
-0.79%
-1.69%
-2.98%
-1.79%
+0.38%
-1.76%
-1.50%
-1.70%
+0.75%
+0.22%
-1.59%
-0.28%
0.00%
-1.59%
+0.77%
-0.92%Popular Symbols
